Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.

Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine.

Licensed seasonal influenza vaccines induce antibody (Ab) responses against influenza hemagglutinin (HA) that are limited in their ability to protect against different strains of influenza. Cytotoxic T lymphocytes recognizing the conserved internal nucleoprotein (NP) and matrix protein (M1) are capa...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Mullarkey, C, Boyd, A, van Laarhoven, A, Lefevre, E, Veronica Carr, B, Baratelli, M, Molesti, E, Temperton, N, Butter, C, Charleston, B, Lambe, T, Gilbert, S
Format:	Journal article
Język:	English
Wydane:	2013

Podobne zapisy

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses
od: Antrobus, R, i wsp.
Wydane: (2014)

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.
od: Antrobus, R, i wsp.
Wydane: (2014)

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.
od: Lillie, P, i wsp.
Wydane: (2012)

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine
od: Powell, T, i wsp.
Wydane: (2013)

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.
od: Timothy J Powell, i wsp.
Wydane: (2013-01-01)

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.
od: Berthoud, T, i wsp.
Wydane: (2011)

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
od: Antrobus, R, i wsp.
Wydane: (2012)

Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
od: Lambe, T, i wsp.
Wydane: (2013)

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.
od: Richard D Antrobus, i wsp.
Wydane: (2012-01-01)

Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies
od: Cécile Janssen, i wsp.
Wydane: (2022-11-01)

Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice
od: Martin C. Langenmayer, i wsp.
Wydane: (2023-06-01)

Adenoviral vectors as novel vaccines for influenza.
od: Coughlan, L, i wsp.
Wydane: (2015)

Novel MVA-based vaccine expressing influenza NP and M1 activates cross-reactive T cell responses in human nasopharynx-associated lymphoid tissue (NALT) (conference abstract)
od: Puksuriwong, S, i wsp.
Wydane: (2018)

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.
od: Lambe, T, i wsp.
Wydane: (2012)

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine
od: Lambe, T, i wsp.
Wydane: (2012)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
od: Ota, M, i wsp.
Wydane: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
od: Ota, M, i wsp.
Wydane: (2011)

Novel bivalent viral-vectored vaccines induce potent humoral and cellular immune responses conferring protection against stringent influenza a virus challenge
od: Tully, C, i wsp.
Wydane: (2017)

Development of NP-Based Universal Vaccine for Influenza A Viruses
od: Ekramy E. Sayedahmed, i wsp.
Wydane: (2024-02-01)

A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed InaCTivated inflUenza vaccine in adultS aged 65 years and above (INVICTUS): a study protocol
od: Swayze, H, i wsp.
Wydane: (2019)

Ipsilateral and contralateral coadministration of influenza and COVID-19 vaccines produce similar antibody responsesResearch in context
od: David Pattinson, i wsp.
Wydane: (2024-05-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
od: Pedro M. Folegatti, i wsp.
Wydane: (2019-03-01)

Uneventful Coadministration of Seasonal Influenza and COVID-19 BNT162b2 Vaccines Two Weeks Post-Influenza Vaccination in an Egg-Allergic Subject: A Case Report
od: Anwar A. Sayed
Wydane: (2023-05-01)

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial
od: Allison R. Thompson, i wsp.
Wydane: (2019-02-01)

Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured onthe AGE1.CR.pIX Avian Cell Line
od: Folegatti, P, i wsp.
Wydane: (2019)

Clinical advances in viral-vectored influenza vaccines
od: Sebastian, S, i wsp.
Wydane: (2018)

Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines
od: Saranya Sridhar, i wsp.
Wydane: (2015-04-01)

Clinical Advances in Viral-Vectored Influenza Vaccines
od: Sarah Sebastian, i wsp.
Wydane: (2018-05-01)

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines
od: Wei Dong, i wsp.
Wydane: (2018-10-01)

Safety of routine childhood vaccine coadministration versus separate vaccination
od: Bauwens, J, i wsp.
Wydane: (2022)

Safety of routine childhood vaccine coadministration versus separate vaccination
od: Simon de Lusignan, i wsp.
Wydane: (2022-09-01)

Preclinical study of immunogenicity of adjuvanted quadrivalent subunit influenza vaccine
od: I. V. Krasilnikov, i wsp.
Wydane: (2022-07-01)

Inactivated recombinant influenza vaccine: the promising direction for the next generation of influenza vaccine
od: Hua Shi, i wsp.
Wydane: (2024-12-01)

Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice
od: Arunkumar, G, i wsp.
Wydane: (2019)

Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge
od: McMahon, M, i wsp.
Wydane: (2019)

Influenza and influenza vaccination in children
od: Viorel ALEXANDRESCU, i wsp.
Wydane: (2017-09-01)

Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach
od: Irene González-Domínguez, i wsp.
Wydane: (2024-11-01)

Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics
od: Kaori Sano, i wsp.
Wydane: (2018-08-01)

Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines
od: Teresa Hauguel, i wsp.
Wydane: (2024-10-01)

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.
od: Boyd, A, i wsp.
Wydane: (2013)